Week 6 is day 42: on a four-week ladder that is week 2 of dose step 2, and — at the seven-day half-life this class runs on — 6 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 42 is 1 weeks past it, which means the level is no longer the variable. That distinction is most of the question: at week 2 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Early satiety is the mechanism rather than a side effect of it — delayed gastric emptying is the intended pharmacology — so the question the week number helps with is whether it is proportionate, not whether it is expected. Dose decisions are made under supervision, and nothing here is medical advice.
To be exact about it, diarrhoea and constipation both occur, which surprises people until they consider how many mechanisms are involved.
Symptom prevalence in trials, broadly: nausea a quarter to a half, diarrhoea and constipation each roughly ten to twenty per cent, vomiting rather less, with all rates rising with dose.
Worth being precise here: symptoms that appear for the first time at a stable dose after months are not the ordinary pattern and warrant looking for another explanation.
Nothing here is medical advice.
Smaller meals, less fat, fluids between rather than with. In that order.
4Any published figure for how long the constipation persists, given it does not attenuate? – e_dziedzic 8 months ago 3The distinction between escalation-related and steady-state is the useful part. – Dr_Jonas_Halvorsen 6 months ago add a comment